|
|||||
|
|
CNS relapse in a low risk acute promyelocytic leukemia patient treated with ATRA-based regimen: is there a role for prophylactic CNS therapy in acute promyelocytic leukemia? |
|
| Authors: | K V Gangadharan Raghuveer Prabhu Neena Mampilly |
| Institution: | (1) Institute of Hematology, Clinical Center for Serbia, Koste Todorovića 2, 11000 Belgrade, Serbia;(2) Medical Faculty, University of Belgrade School of Medicine, Dr Subotić 9, Belgrade, Serbia;(3) Laboratory for Molecular Hematology, Institute of Molecular Genetics and Genetic Engineering, Vojvode Stepe 444a, PO Box 23, 11010 Belgrade, Serbia;(4) North Middlesex University Hospital, Sterling Way, London, N18 1QX, UK |
| Abstract: | Though the incidence of CNS relapse in acute promyelocytic leukemia (AML-M3 FAB classification) has increased following the advent of all-trans retinoic acid (ATRA), still CNS relapse accounts for only 2–3% of all relapses in AML-M3 trated with standard ATRA plus chemotherapy regimen. We report a case of low risk AML-M3 treated with standard therapy, developing CNS relapse while on maintenance therapy with ATRA + 6-mercaptopurine (6-MP) + methotrexate (MTX). |
| Keywords: | Acute promyelocytic leukemia CNS relapse Prophylactic CNS therapy All-trans retinoic acid |
| 本文献已被 SpringerLink 等数据库收录！ | |